|
|
| Unaudited Financial Results for the Quarter ended 30th June, 2008 |
|
|
Stand alone |
Consolidated |
|
First Quarter Ended |
Year Ended |
First Quarter Ended |
Year ended |
Particulars |
30.06.2008 |
30.06.2007 |
31.03.2008 |
30.06.2008 |
31.03.2007 |
31.03.2008 |
|
(Unaudited) |
(Unaudited) |
(Audited) |
(Unaudited) |
(Unaudited) |
(Audited) |
| Sales(including excise duty) |
6,744 |
5,087 |
23,511 |
7,068 |
5,611 |
25,523 |
| Less: Excise Duty |
271 |
287 |
1,164 |
271 |
288 |
1,164 |
| Net Sales |
6,473 |
4,800 |
22,347 |
6,797 |
5,323 |
24,359 |
| Other Operating Income |
58 |
33 |
582 |
35 |
33 |
106 |
| Other Income |
7 |
7 |
118 |
15 |
8 |
144 |
| Total Income |
6,538 |
4,840 |
23,047 |
6,847 |
5,364 |
24,609 |
| Expenditure |
|
|
|
|
|
|
| a. (Increase)/ Decrease in Stock |
2 |
(345) |
(347) |
(100) |
(440) |
(712) |
| b. Material Consumed |
3,793 |
3,240 |
13,755 |
3,572 |
3,037 |
12,612 |
| c. Purchase of traded goods |
16 |
45 |
118 |
217 |
330 |
1,615 |
| d. Staff Cost |
437 |
337 |
1,487 |
574 |
442 |
1,930 |
| e. Depreciation/ Amortisation |
195 |
174 |
746 |
270 |
234 |
1,004 |
| f. Other Expenditure |
1,027 |
984 |
4,160 |
1,425 |
1,259 |
5,504 |
| Total expenditure |
5,470 |
4,435 |
19,919 |
5,958 |
4,862 |
21,953 |
| Profit Before, Interest & Tax |
1,068 |
405 |
3,128 |
889 |
502 |
2,656 |
| Interest (net) |
71 |
44 |
161 |
132 |
106 |
432 |
| Foreign Exchange (Gain)/ Loss |
560 |
(289) |
(481) |
537 |
(294) |
(693) |
| Profit from Ordinary Activities before tax |
437 |
650 |
3,448 |
220 |
690 |
2,917 |
| Provision for Taxation |
|
|
|
|
|
|
| a. Current Tax (MAT) |
49 |
76 |
484 |
65 |
81 |
479 |
| b. MAT Credit Entitlement |
(41) |
(4) |
- |
(41) |
(4) |
- |
| c. Deferred Tax |
10 |
8 |
52 |
10 |
(8) |
52 |
| d. Fringe Benefit Tax (net of recovery) |
1 |
1 |
5 |
1 |
1 |
5 |
| e. Tax adjustments of previous years |
20 |
- |
- |
20 |
- |
- |
| Total Tax |
39 |
65 |
541 |
55 |
70 |
536 |
| Profit before Minority Interest |
398 |
585 |
2,907 |
165 |
620 |
2,381 |
| Minority Interest |
|
|
|
1 |
3 |
(3) |
| Net Profit for the period |
398 |
585 |
2,907 |
164 |
617 |
2,384 |
| Paid-up Equity Share Capital |
268.82 |
266.74 |
268.82 |
268.82 |
266.74 |
268.82 |
| (Face value Rs. 5 per share) |
|
|
|
|
|
|
| Reserves excluding Revaluation Reserves |
|
|
11,937 |
|
|
10,971 |
| Basic Earnings per share before & after Extraordinary items (Rs.) (not annualised) |
7.42 |
10.97 |
54.21 |
3.06 |
11.57 |
44.46 |
| Diluted Earnings per share before & after Extraordinary items (Rs.) (not annualised) |
5.90 |
8.66 |
43.07 |
2.43 |
9.13 |
35.33 |
| Public Shareholding |
|
|
|
|
|
|
| a. Number of Shares |
24,049,036 |
26,636,405 |
24,049,036 |
24,049,036 |
26,636,405 |
24,049,036 |
| b. Percentage of Shareholding |
44.73 |
44.31 |
44.73 |
44.73 |
44.31 |
44.73 |
|
|
|
| Notes: |
| 1. |
The above unaudited financial results were reviewed by the Audit Committee and have been approved by the Board at its meeting held on 30.07.2008. The quarterly stand alone results are subject to Limited Review by Auditors of the Company. |
| 2. |
The Consolidated financial results, which are optional, have been presented by the Company, so as to provide additional information. |
| 3. |
The consolidated financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement', AS-27 ' Financial Reporting of Interests in Joint Ventures' and includes financial results of all subsidiaries and 50:50 Joint Ventures. |
| 4. |
The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'. |
| 5. |
Investor complaints pending at the beginning of the quarter: Nil, received: 45, resolved:45 and lying unresolved at the end of the quarter Nil. |
| 6. |
Sales for the quarter include exports of Rs.4386.8 Millions (Rs.2772.0 Millions). |
| 7. |
Other Operating Income represents sale of dossier. |
| 8. |
Foreign Exchange (Gain)/Loss represents exchange differences arising during the period on all foreign currency transactions. This includes Loss due to restatement of Foreign Currency Convertible Bonds (net of Deposits) Rs.566.2 Millions (Gain of Rs.408.5 Millions). |
| 9. |
Premium on redemption of USD 255.5 Million zero coupon Foreign Currency Convertible Bonds is contingent in nature, the outcome of which is dependant on uncertain future events. |
| 10. |
During the quarter, the Company has formed a new step-down subsidiary viz., Aurobindo Pharma (Portugal) Unipessoal Limitada. |
| 11. |
Figures for the previous periods have been rearranged/regrouped wherever necessary to make it comparable. |
|
|
|
|
For and on behalf of the Board |
|
|
Sd/- |
| Place: Hyderabad |
|
K.Nityananda Reddy |
| Date : 30.07.2008 |
|
Managing Director |
|
|
|
